KCG Holdings Inc. reduced its position in shares of Amarin Corporation PLC (NASDAQ:AMRN) by 65.9% during the first quarter, Holdings Channel reports. The fund owned 40,245 shares of the biopharmaceutical company’s stock after selling 77,843 shares during the period. KCG Holdings Inc.’s holdings in Amarin Corporation PLC were worth $129,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Renaissance Technologies LLC boosted its position in Amarin Corporation PLC by 348.2% in the first quarter. Renaissance Technologies LLC now owns 1,730,200 shares of the biopharmaceutical company’s stock worth $5,537,000 after buying an additional 1,344,200 shares during the last quarter. Morgan Stanley boosted its position in Amarin Corporation PLC by 119.7% in the first quarter. Morgan Stanley now owns 1,138,992 shares of the biopharmaceutical company’s stock worth $3,645,000 after buying an additional 620,577 shares during the last quarter. UBS Group AG boosted its position in Amarin Corporation PLC by 7.4% in the first quarter. UBS Group AG now owns 731,518 shares of the biopharmaceutical company’s stock worth $2,341,000 after buying an additional 50,200 shares during the last quarter. California Public Employees Retirement System boosted its position in Amarin Corporation PLC by 13.3% in the first quarter. California Public Employees Retirement System now owns 533,300 shares of the biopharmaceutical company’s stock worth $1,707,000 after buying an additional 62,800 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its position in Amarin Corporation PLC by 27.1% in the first quarter. JPMorgan Chase & Co. now owns 35,590 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 7,580 shares during the last quarter. Hedge funds and other institutional investors own 37.57% of the company’s stock.

Shares of Amarin Corporation PLC (NASDAQ:AMRN) traded down 0.6677% on Thursday, hitting $3.3177. 245,169 shares of the stock traded hands. The stock’s market cap is $898.41 million. The stock’s 50 day moving average price is $3.87 and its 200 day moving average price is $3.31. Amarin Corporation PLC has a 52-week low of $2.56 and a 52-week high of $4.47.

Amarin Corporation PLC (NASDAQ:AMRN) last released its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01. The company had revenue of $44.95 million during the quarter, compared to analyst estimates of $40.35 million. The firm’s revenue for the quarter was up 37.0% on a year-over-year basis. During the same quarter last year, the business earned ($0.07) earnings per share. On average, equities analysts expect that Amarin Corporation PLC will post ($0.22) EPS for the current fiscal year.

WARNING: This article was reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://www.watchlistnews.com/kcg-holdings-inc-has-129000-position-in-amarin-corporation-plc-amrn/1470617.html.

A number of equities analysts have issued reports on the stock. BidaskClub upgraded shares of Amarin Corporation PLC from a “buy” rating to a “strong-buy” rating in a research report on Thursday, July 6th. Zacks Investment Research raised shares of Amarin Corporation PLC from a “sell” rating to a “hold” rating in a research note on Monday, July 3rd. Jefferies Group LLC lifted their target price on shares of Amarin Corporation PLC from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Friday, June 30th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Amarin Corporation PLC in a research note on Thursday, August 3rd. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Amarin Corporation PLC has a consensus rating of “Buy” and an average price target of $7.35.

In other Amarin Corporation PLC news, General Counsel Joseph T. Kennedy sold 307,911 shares of Amarin Corporation PLC stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $4.00, for a total transaction of $1,231,644.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 3.72% of the stock is owned by company insiders.

Amarin Corporation PLC Company Profile

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Want to see what other hedge funds are holding AMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amarin Corporation PLC (NASDAQ:AMRN).

Institutional Ownership by Quarter for Amarin Corporation PLC (NASDAQ:AMRN)

Receive News & Ratings for Amarin Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin Corporation PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.